Investor
Eli Lilly
Named as a participating investor in 8 funding announcements in 2026. Every round below links to the announcement that named them.
For investors, banks and advisers
Want this delivered, filtered to your mandate?
Every morning: the rounds in your sectors, stages and regions. The investor index as an export. First access to what verified founders say their companies need next, on the founder's terms. Tell us what you are looking for and a person replies with what is available for your desk.
Where it invests
Sectors named in these rounds
Invests alongside
Named on the same announcements
Counted from the announcements only. Appearing on the same round is a fact about the round, not a statement about a relationship.
Rounds joined
Where Eli Lilly participated
| Company | Raised | Round | Announced | Led by | Source |
|---|---|---|---|---|---|
| Circle Pharma USA | $92M | Series E | 2026-09-16 | led by Column Group | announcement |
| Moonwalk Biosciences USA | $70M | Series B | 2026-09-08 | led by Alpha Wave, YK Bioventures | announcement |
| Cloverleaf Bio USA | $33M | Seed | 2026-09-08 | led by 4BIO Capital | announcement |
| Superluminal Medicines USA | $60M | Series B | 2026-09-03 | led by BVF Partners | announcement |
| InduPro USA | $77M | Series B | 2026-08-13 | led by Column Group | announcement |
| Amplifica USA | $26M | Series B | 2026-08-12 | led by Tasso Partners | announcement |
| Remedium Bio USA | $10M | Series A | 2026-08-10 | led by Lifespan Vision Ventures | announcement |
| Lycia Therapeutics USA | $75M | Series D | 2026-06-29 | led by Janus Henderson Investors, Balyasny Asset Management | announcement |
Investor names are read from the funding announcements and grouped by spelling. A round names its investors the way the publisher did; a firm not named in an announcement does not appear here. Corrections: info@afterraise.com.